QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors. (15th April 2019)

• Record Type: Journal Article
• Authors: Fatima, Shehnaz; Pal, Divyani; Agarwal, Subhash Mohan
• Is Part Of: Chemical biology & drug design. Volume 94:Number 1(2019)
• Page Start: 1306
• Page End: 1315
• Publication Date: 2019-04-15
• Subjects: double mutant inhibitor -- EGFR -- irreversible inhibitors -- QSAR -- T790M -- Williams plot; Drugs -- Design -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; 615.19005
• DOI: 10.1111/cbdd.13505
• Languages: English
• ISSNs: 1747-0277

Abstract

Abstract: EGFR is a well‐established therapeutic target of clinical relevance in cancer. However, acquisition of secondary mutation (T790M) makes first‐generation inhibitors ineffective. Therefore, to circumvent the problem of resistance, new T790M/L858R (TMLR) double mutant inhibitors are required. In this study, fragment‐based QSAR models (GQSAR) were generated for pyridinylimidazole derivatives having biological activity against TMLR mutants. The GQSAR model developed using partial least squares regression via stepwise forward–backward variable selection technique showed best results as judged using statistical parameters ( r 2, q 2, and pred_ r 2 ). Additionally, applicability domain of the model was verified using Williams plot, which indicated that the predicted data are reliable. The GQSAR provided site‐specific clues wherein modifications related to decreasing lipophilic character and rotatable bonds and increasing SaaCHE‐index are required for improving inhibitory activity. Overall, the study indicated that the presence of acrylamide at R5 is essential for covalent bond formation with Cys797 and occurrence of aromatic residue at R2 is required for occupying hydrophobic region next to Met790 gatekeeper residue. Based on this information, new derivatives were designed that show better inhibitory activity than the experimentally reported most active molecules. Thus, the model developed can be used to design new pyridinylimidazole derivatives with improved TMLR bioactivity. Abstract : EGFR is a clinically important drug target in lung cancer. However, occurrence of secondary mutation makes first‐generation inhibitors ineffective and thus new inhibitors are needed. Therefore, we have generated QSAR models of pyridinylimidazole‐based TMLR inhibitors to identify descriptors that regulate bioactivity. We discuss contributions of important descriptors and provide clues for the design of newer inhibitors. We also design few derivatives that exhibit better inhibitory activity and thus expect the study to provide insight for designing of potent EGFR mutant inhibitors.